Protocol Ledger

NCT04983043 · Phase II · COMPLETED

Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure

Interventional Phase II clinical trial protocol NCT04983043 sponsored by Tasly Pharmaceutical Group Co in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-07-13 Enrollment: 228 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04983043
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)228 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04983043
Protocol FieldVerified Registry Value
NCT IdentifierNCT04983043
Consolidated Lead SponsorTasly Pharmaceutical Group Co
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment228 participants (ACTUAL)
Registered Start Date2021-07-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04983043
Hospital Research SiteLocationSite Profile
Nanfang Hospital, Southern Medical UniversityGuangzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI